Table 5. Subgroup analysis of patients without cirrhosis.

SVR12: sustained virologic response at 12 weeks post-treatment; HB: hemoglobin.

		SVR12		Total	p-value
		Achieved	Not achieved
Age	21-40 years	34 (97.1%)	1 (2.9%)	35 (100.0%)	0.414
	41-60 years	23 (100.0%)	0 (0.0%)	23 (100.0%)
Disease duration	Less than 12 months	40 (97.6%)	1 (2.4%)	41 (100.0%)	0.516
	More than 12 months	17 (100.0%)	0 (0.0%)	17 (100.0%)
HB	Less than 10 gm/dl	8 (88.9%)	1 (11.1%)	9 (100.0%)	0.019
	More than 10 gm/dl	49 (100.0%)	0 (0.0%)	49 (100.0%)
Serum albumin	More than 3.5 gm/dl	13 (100.0%)	0 (0.0%)	13 (100.0%)	0.588
	Less than 3.5 gm/dl	44 (97.8%)	1 (2.2%)	45 (100.0%)
Gender	Male	35 (97.2%)	1 (2.8%)	36 (100.0%)	0.430
	Female	22 (100.0%)	0 (0.0%)	22 (100.0%)
Platelet count	Less than 150000	8 (88.9%)	1 (11.1%)	9 (100.0%)	0.019
	More than 150000	49 (100.0%)	0 (0.0%)	49 (100.0%)